Goldman Sachs’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-798,544
| Closed | -$16.1M | – | 6875 |
|
|
2021
Q3 | $16.1M | Buy |
798,544
+188,090
| +31% | +$5.19M | ﹤0.01% | 2273 |
|
|
2021
Q2 | $22.8M | Sell |
610,454
-458,115
| -43% | -$14M | 0.01% | 1935 |
|
|
2021
Q1 | $27.3M | Sell |
1,068,569
-10,304
| -1% | -$263K | 0.01% | 1671 |
|
|
2020
Q4 | $23.8M | Buy |
1,078,873
+377,291
| +54% | +$8.31M | 0.01% | 1723 |
|
|
2020
Q3 | $12.6M | Buy |
701,582
+176,149
| +34% | +$3.65M | ﹤0.01% | 2114 |
|
|
2020
Q2 | $13.3M | Sell |
525,433
-676,674
| -56% | -$14.6M | ﹤0.01% | 2031 |
|
|
2020
Q1 | $22.1M | Buy |
1,202,107
+441,229
| +58% | +$8.58M | 0.01% | 1432 |
|
|
2019
Q4 | $16.8M | Sell |
760,878
-22,139
| -3% | -$446K | ﹤0.01% | 2014 |
|
|
2019
Q3 | $11.2M | Sell |
783,017
-551,629
| -41% | -$7.88M | ﹤0.01% | 2230 |
|
|
2019
Q2 | $21M | Buy |
1,334,646
+220,898
| +20% | +$3M | 0.01% | 1818 |
|
|
2019
Q1 | $16.3M | Sell |
1,113,748
-118,514
| -10% | -$1.36M | ﹤0.01% | 2041 |
|
|
2018
Q4 | $13.2M | Sell |
1,232,262
-124,522
| -9% | -$1.64M | ﹤0.01% | 2139 |
|
|
2018
Q3 | $20.7M | Buy |
1,356,784
+804,970
| +146% | +$11.7M | 0.01% | 1887 |
|
|
2018
Q2 | $6.76M | Sell |
551,814
-236,790
| -30% | -$2.97M | ﹤0.01% | 2738 |
|
|
2018
Q1 | $7.54M | Buy |
788,604
+594,406
| +306% | +$6.41M | ﹤0.01% | 2584 |
|
|
2017
Q4 | $1.75M | Buy |
194,198
+88,778
| +84% | +$653K | ﹤0.01% | 3895 |
|
|
2017
Q3 | $606K | Buy |
+105,420
| New | +$384K | ﹤0.01% | 4966 |
|
|
2017
Q1 | – | Sell |
-24,286
| Closed | -$70K | – | 7095 |
|
|
2016
Q4 | $70K | Sell |
24,286
-18,855
| -44% | -$67K | ﹤0.01% | 6293 |
|
|
2016
Q3 | $254K | Sell |
43,141
-328
| -0.8% | -$1.15K | ﹤0.01% | 5608 |
|
|
2016
Q2 | $130K | Buy |
43,469
+12,297
| +39% | +$50.5K | ﹤0.01% | 5990 |
|
|
2016
Q1 | $167K | Buy |
31,172
+15,373
| +97% | +$97K | ﹤0.01% | 5759 |
|
|
2015
Q4 | $188K | Buy |
15,799
+2,567
| +19% | +$29.4K | ﹤0.01% | 5763 |
|
|
2015
Q3 | $109K | Sell |
13,232
-10,402
| -44% | -$120K | ﹤0.01% | 6430 |
|
|
2015
Q2 | $330K | Buy |
+23,634
| New | +$433K | ﹤0.01% | 5637 |
|
|
2014
Q2 | – | Sell |
-9,079
| Closed | -$256K | – | 7202 |
|
|
2014
Q1 | $256K | Buy |
+9,079
| New | +$337K | ﹤0.01% | 5858 |
|
Other funds holding DRNA
Goldman Sachs's DRNA Position: Q4 2021 in Review
Goldman Sachs sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 798,544 shares — an estimated $16.1M sold.
Goldman Sachs first reported a position in DRNA in Q1 2014 and held it in 25 quarters. The position peaked at $27.3M in Q1 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.
- Goldman Sachs reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
- Goldman Sachs sold 798,544 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $16.1M.
- Goldman Sachs first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2014 and held it in 25 quarters.
- Goldman Sachs's Dicerna Pharmaceuticals, Inc. position peaked at $27.3M in Q1 2021.
- 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.
Based on Goldman Sachs's 13F filing for Q4 2021, filed 14 Feb 2022.